Corcept Therapeutics Incorporated (NASDAQ: CORT) has captured the attention of investors with its promising growth trajectory within the biotechnology sector. Headquartered in Redwood City, California, Corcept specializes in the discovery and development of treatments for a range of severe disorders, including endocrinologic, oncologic, metabolic, and neurologic conditions. The company’s flagship product, Korlym, is a pivotal treatment for hypercortisolism, specifically targeting adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Corcept’s development pipeline is robust, with several promising candidates at…